Acalabrutinib Shows Lower Cardiac Failure Rates Than Ibrutinib in CLL Treatment
The first-generation BTK inhibitor, ibrutinib, is known to increase the risk of cardiac arrhythmias and heart failure. To address this concern, a study examined heart failure occurrence in CLL patients treated with the second-generation BTK inhibitor, acalabrutinib. Paolo Ghia, Professor at Università Vita-Salute San Raffaele in Italy, shares the trial results in this EHA23 MEDtalk, that provides insights into the cardiac safety of acalabrutinib.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.